Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "GSK"

75 News Found

GSK completes acquisition of Aiolos Bio
News | February 19, 2024

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody


GSK Q3 FY 2023-24 revenue at Rs. 805 Cr
News | February 13, 2024

GSK Q3 FY 2023-24 revenue at Rs. 805 Cr

The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India


GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
News | January 10, 2024

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway


GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
News | November 28, 2023

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex


GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Drug Approval | November 21, 2023

GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia

Decision on EU marketing authorisation expected for momelotinib by early 2024


GSK registers 5% revenue growth in Q2 FY24
News | November 10, 2023

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix


GSK receives USFDA Fast Track designation for investigational vaccine against gonorrhoea
News | June 28, 2023

GSK receives USFDA Fast Track designation for investigational vaccine against gonorrhoea

Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing


Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
News | June 13, 2023

Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData

Pfizer is likely to show GSK significant competition


GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer
Drug Approval | June 12, 2023

GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer

Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities


European Commission authorises GSK’s Arexvy for older adults
Drug Approval | June 08, 2023

European Commission authorises GSK’s Arexvy for older adults

Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time